Generate Biomedicines, Inc. (NASDAQ:GENB)
| Market Cap | 1.82B+11.9% |
| Revenue (ttm) | 13.54M |
| Net Income | -128.70M |
| EPS | -1.06 |
| Shares Out | 128.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 636,267 |
| Open | 14.27 |
| Previous Close | 13.85 |
| Day's Range | 13.40 - 14.34 |
| 52-Week Range | 11.00 - 22.67 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 26.00(+83.62%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About GENB
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Insider buys and sells on the price
1 year · open-market trades onlyAnalyst consensus
1 firm rating GENB in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 5, 2026Earnings report
Ask Barron about GENB
$GENB stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GENB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GENB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GENB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GENB Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| External - discovery related costs and other | $16.88M | 53.70% |
| Stock-based compensation | $8.24M | 26.21% |
| Collaboration revenue | $6.31M | 20.09% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GENB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GENB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GENB
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $28.39M |
| ARKGARK Genomic Revolution ETF | $22.79M |
| IWMiShares Russell 2000 ETF | $8.66M |
| VXFVanguard Extended Market ETF | $4.24M |
| JTEKJPMorgan U.S. Tech Leaders ETF | $3.99M |
| IWOiShares Russell 2000 Growth ETF | $2.21M |
Estimated from each fund’s disclosed top holdings × AUM
GENB Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GENB’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 96 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 59.6
What’s Behind the Score
News check: GENB stock jumped 17% with conference participation noted; one headline suggests valuation concerns but most coverage is neutral event-based news without negative catalysts.